• Home
  • Our Pipeline
  • About Us
  • Science
    • Active Immunotherapies
    • GlyMab®
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Scancell to Present at 2024 AACR Annual Meeting

by admin | Apr 4, 2024 | Latest News, Regulatory News, SCIB1

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell Attends and Sponsors the Annual Melanoma Patient Meeting

by admin | Mar 11, 2024 | Interviews, Latest News, SCIB1

Scancell Attends and Sponsors the Annual Melanoma Patient Meeting By Lucia Turnes, Senior Clinical Research Associate Clinical trials are increasingly becoming more complex, with stratification of treatment options based on presentation of disease. Patients have more...

MHRA approval to add a third cohort using iSCIB1+ to the SCOPE trial

by admin | Jan 17, 2024 | Latest News, Regulatory News, SCIB1

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Update on SCOPE trial

by admin | Nov 28, 2023 | Latest News, Regulatory News, SCIB1

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell presents positive data from the first stage in its Phase 2 SCOPE trial at the 20th International Congress of the Society for Melanoma Research

by admin | Nov 10, 2023 | Immunobody, Latest News, Regulatory News, SCIB1

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell announces late-breaking abstract presenting positive data from the first stage in its Phase 2 SCOPE trial

by admin | Nov 1, 2023 | Latest News, Regulatory News, SCIB1

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Scancell announces CFO Transition
  • Edison Report – Redesigning immunity: The next frontier in immuno-oncology
  • Scancell Financial Year 2026 Interim Results
  • H126: solid iSCIB1+ data underpins planned progress
  • Interim Results and Business Update

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy